Hydroxychloroquin Aristo (Hydroxychloroquine Sulfate)

Hydroxychloroquine interferes with the parasite’s ability to detoxify heme, leading to toxic buildup that kills malaria organisms. In immune cells, it raises lysosomal pH, inhibiting autophagy and antigen processing, which reduces cytokine release and dampens inflammatory activity.

The specific dose of Hydroxychloroquin Aristo is determined by the prescribing clinician based on the patient’s condition, weight, renal function and other factors. Only a qualified health professional should set the dosage regimen.

Safety data for hydroxychloroquine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a healthcare provider.

To request Hydroxychloroquin Aristo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Hydroxychloroquine differs from agents such as chloroquine or artemisinin‑based combinations by its dual antimalarial and immunomodulatory actions. It is generally better tolerated than chloroquine but requires monitoring for retinal toxicity, a concern less prominent with some newer antimalarials.

Hydroxychloroquin Aristo should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Hydroxychloroquin Aristo is taken orally, usually with a full glass of water. The tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse effects include retinal toxicity that can lead to permanent vision loss, cardiac complications such as cardiomyopathy or QT prolongation, severe hypoglycemia, and rare blood disorders like agranulocytosis. Prompt reporting of symptoms is essential.

Patients with known hypersensitivity to hydroxychloroquine or other 4‑aminoquinoline compounds should avoid the product. It is also contraindicated in individuals with pre‑existing retinal disease, severe cardiac conduction disorders, or those taking interacting medications that cannot be safely managed.